H464 (located in DIIIa) appears to have the biggest effect on FcRn binding and attenuation of blood circulation persistence. Db (2.9 h). Biodistribution confirmed the order of blood clearance from sluggish to fast: Db-DIII WT > H535A > H510A > H464A > Db with 4.0, 2.0, 1.8, 1.6 and 0.08 %ID/g of remaining blood activity at 51 h, respectively. This study demonstrates that attenuating the PF-04979064 DIIIFcRn conversation provides a way of controlling the pharmacokinetics of the entire Db-DIII fusion protein without compromising tumor targeting. H464 appears to be most crucial for FcRn binding (greatest reduction in MRT), followed by H510 and H535. By mutating the DIII scaffold, we can dial serum kinetics for imaging or therapy applications. Keywords:blood clearance, FcRn, HSA DIII, PET imaging, protein scaffold == Introduction == Within the past decade, combinatorial library technology has yielded a large number of molecules, including peptides, aptamers and small chemical molecules, selected to bind various targets or tissues with great specificity and affinity (Ainaet al., 2007;Barbas and White, 2009;Bembeneket al., 2009). Yet, when administeredin vivo, these molecules often exhibit suboptimal pharmacokinetics characterized by transient serum persistence and failure to accumulate at the target site to sufficient levels for either imaging or therapy applications. To address this problem, we proposed the following hypothesis. If low molecular weight tumor targeting molecules are attached, grafted or displayed onto a protein scaffold characterized by intrinsic serum stability, then improved pharmacokinetic profile and target uptake can be achieved. Maximizing tumor accumulation could potentially translate into a stronger signal in imaging applications or a sufficient drug payload delivery in therapy. In addition, the scaffold can provide residues for conjugation of a functional group (e.g. radionuclide, cytotoxic drug, toxin) and may also enhance the solubility of hydrophobic-targeting molecules. An ideal scaffold should be (i) non-immunogenic, (ii) capable of providing optimal serum persistence for different applications (tunable), (iii) low in molecular mass, facilitating extravasation, tumor penetration and renal clearance (<60 kDa), which is preferable for imaging software, (iv) a platform for increasing the functional affinity of targeting molecules by using the avidity effect (23 targeting molecules on the same scaffold) or introducing multiple specificities, and (v) soluble in serum, rendering molecules attached to its surface also soluble. Human serum albumin (HSA; 67 kDa) is the most abundant protein in the human blood (3050 g/l) and has already been incorporated into an approved pharmaceutical (i.e. Albuferon, Novartis). In preclinical studies, HSA has successfully been utilized as a carrier molecule PF-04979064 for drug delivery (Kratzet al., 2000;Burgeret al., 2001;Wosikowskiet al., 2003) and a vector for gene delivery (Ainaet al., 2007). As a fusion protein, HSA has exhibited its ability to improve the pharmacokinetics of molecules, such as interferon- (Osbornet al., 2002), interleukin-2 (Melderet al., 2005), recombinant bispecific antibody molecule (Mulleret al., 2007) or scFv antibody fragment (Yazakiet al., 2008). Much like IgG, HSA interacts with the neonatal Fc receptor (FcRn), also known as Brambell receptor (Chaudhuryet al., 2003). This conversation is responsible for the extended serum persistence of albumin. It is likely that albumin traffics in the same way as IgG, according to the following model. Albumin FST molecules in the blood circulation are taken by vascular endothelial cells through fluid phase endocytosis. Albumin binds the FcRn in the early endosome (pH 6.0). Most FcRn bound albumin leaves the early endosome in tubulovesicular recycling compartments. These compartments transcytose or move to the cell surface PF-04979064 and exocytose, releasing albumin back in blood (pH 7.4). The late endosome either fuses completely or partially to a lysosome, delivering its content for degradation (Ganet al., 2009). Specifically, HSA domain name III (DIII; 23 kDa) has been shown to be both necessary and sufficient for FcRn binding in a pH-dependent manner (Chaudhuryet al., 2006). Owing to the.